The therapeutic armamentarium for chronic myeloid leukaemia (CML) comprises mainly
tyrosine kinase inhibitors (TKIs), with several agents available for frontline treatment, or for …

Most patients with chronic myeloid leukemia have deep and durable responses when
treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs). Imatinib (the first approved TKI) …

Purpose A dramatic improvement in the survival of patients with chronic myeloid leukemia
(CML) occurred after the introduction of imatinib mesylate, the first tyrosine kinase inhibitor …

Vascular and cardiac safety during tyrosine kinase inhibitor (TKI) therapy is an emerging
issue. We evaluated vascular/cardiac toxicities associated with long‐term bosutinib …

Current treatment recommendations for chronic myeloid leukemia (CML) are guided by
results from multiple clinical trials involving tyrosine kinase inhibitors that target BCR-ABL1 …

The introduction of tyrosine kinase inhibitors has improved outcomes in Philadelphia
chromosome-positive acute lymphoblastic leukemia, yet relapse due to the development of …

В обзоре представлен анализ актуальных литературных данных, демонстрирующих
патофизиологические механизмы развития сердечно-сосудистых осложнений химио-и …

Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are available for the treatment of chronic
myeloid leukemia in chronic phase (CML-CP), and several baseline and on-treatment …

The review presents an analysis of current literature data demonstrating the
pathophysiological mechanisms of the development of cardiovascular complications of …

The use of tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia has
significantly altered the prognosis of this disease, enabling close to normal life expectancy …